Endogenous α2-antiplasmin is protective during severe gram-negative sepsis (Melioidosis)

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 8, 2013, Pages 967-975

  Kager, Liesbeth M ^a   Weehuizen, Tassili A ^a   Wiersinga, W Joost ^a   Roelofs, Joris J T H ^a   Meijers, Joost C M ^a   Dondorp, Arjen M ^b,c   Van't Veer, Cornelis ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAHIDOL UNIVERSITY   (Thailand)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

2 antiplasmin; Coagulation; Fibrinolysis; Melioidosis; Sepsis

Indexed keywords

ALPHA 2 ANTIPLASMIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; LETHALITY; LUNG HOMOGENATE; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MELIOIDOSIS; MOUSE; NEUTROPHIL; NONHUMAN; OBSERVATIONAL STUDY; ORGAN INJURY; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-2-ANTIPLASMIN; ANIMALS; BACTERIAL LOAD; BURKHOLDERIA PSEUDOMALLEI; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION; LUNG; MALE; MELIOIDOSIS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MIDDLE AGED; SEPSIS; YOUNG ADULT;

EID: 84886381344     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201307-1344OC     Document Type: Article

References (39)

1. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010;38:S26-S34.
2. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.
3. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 2000;28:S77-S80.
4. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592.
5. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007;5:812-817.
6. Coughlin PB. Antiplasmin: the forgotten serpin? FEBS J 2005;272:4852-4857.
7. Carpenter SL, Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008;14:1250-1254.
8. Matsuno H, Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, Okada K, Ueshima S, Matsuo O, Uematsu T. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood 2002;100:2487-2493.
9. Bagge L, Haglund O, Wallin R, Borg T, Modig J. Differences in coagulation and fibrinolysis after traumatic and septic shock in man. Scand J Clin Lab Invest 1989;49:63-72.
10. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990;57:271-278.
11. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536-1542.
12. Mavrommatis AC, Theodoridis T, Economou M, Kotanidou A, El AM, Christopoulou-Kokkinou V, Zakynthinos SG. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 2001;27:1853-1859.
13. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik HC. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001;86:543-549.
14. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, Hazelzet JA. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003;31:1839-1847.
15. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:454-462.
16. Song Y, Lynch SV, Flanagan J, Zhuo H, Tom W, Dotson RH, Baek MS, Rubio-Mills A, Singh G, Kipnis E, et al. Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology 2007;106:252-261.
17. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006;118:205-212.
18. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, van der Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004;59:130-135.
19. Choi G, SchultzMJ, van Till JW, Bresser P, van der Zee JS, Boermeester MA, Levi M, van der Poll T. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection.Eur Respir J 2004;24:786-789.
20. Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo CH, Xu H, Bourne P, Ha UH, Ishinaga H, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007;27:349-360.
21. Renckens R, Roelofs JJ, Bonta PI, Florquin S, de Vries CJ, Levi M, Carmeliet P, van't Veer C, van der Poll T. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 2007;109:1593-1601.
22. Kager LM, Wiersinga WJ, Roelofs JJ, Meijers JC, Levi M, van't Veer C, van der Poll T. Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis). J Thromb Haemost 2011;9:2020-2028.
23. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005;3:35-45.
24. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010;4:e900.
25. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005;18:383-416.
26. Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med 2012; 367:1035-1044.
27. Butler D. Viral research faces clampdown. Nature 2012;490:456.
28. Kager LM, Wiersinga WJ, Roelofs JJ, Meijers JC, Levi M, van't Veer C, van der Poll T. Endogenous tissue-type plasminogen activator impairs host defense during severe experimental gram-negative sepsis (melioidosis). Crit Care Med 2012;40:2168-2175.
29. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, Limmathurotsakul D, Chierakul W, Leendertse M, Florquin S, de Vos AF, et al. Toll-like receptor 2 impairs host defense in gramnegative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med 2007;4:e248.
30. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999;93:2274-2281.
31. Kanno Y, Kuroki A, Okada K, Tomogane K, Ueshima S, Matsuo O, Matsuno H. Alpha2-antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis. J Thromb Haemost 2007;5:2266-2273.
32. Iba T, Kidokoro A, Fukunaga M, Sugiyama K, Sawada T, Kato H. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005; 23:25-29.
33. Wiersinga WJ, Meijers JC, Levi M, van 't Veer C, Day NP, Peacock SJ, van der Poll T. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 2008;6:32-39.
34. Levi M, Schultz MJ, Rijneveld AW, van der Poll T. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003;31:S238-S242.
35. Kanno Y, Kawashita E, Minamida M, Kaneiwa A, Okada K, Ueshima S, Matsuo O, Matsuno H. alpha2-antiplasmin is associated with the progression of fibrosis. Am J Pathol 2010;176:238-245.
36. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem 2010;147: 781-792.
37. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
38. Weehuizen TA, Wieland CW, van der Windt GJ, Duitman JW, Boon L, Day NP, Peacock SJ, van der Poll T, Wiersinga WJ. Expression and function of transforming growth factor beta in melioidosis. Infect Immun 2012;80:1853-1857.
39. Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 2007;195:99-107.